Testoluten 20mg
An oral animal-derived testicular peptide extract explored in bioregulator research for male endocrine and reproductive support.
Mechanism
The preparation is hypothesized to deliver short, tissue-homologous peptide sequences that modulate gene expression and protein synthesis within testicular target tissues, including Leydig and germinal cells.
Dosing
Standard research protocols document an introductory oral dose of 20 mg (1 capsule) daily.
Reconstitution
As an encapsulated oral preparation, this agent requires no bacteriostatic water or liquid reconstitution.
Storage
Store sealed capsules in a dry, dark environment maintained at controlled room temperature.
Mix & measure Testoluten 20mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Testoluten 20mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: —
U-100 syringe: 100 units = 1 mL
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Initial Phase (Days 1–10) | 20 mg (1 capsule) once daily | Oral capsule (N/A) |
| Intensive Phase (Days 11–30) | 40 mg (2 capsules) once daily | Oral capsule (N/A) |
| Maintenance Phase | 20–40 mg daily for 10–30 days (repeat 2–3x/year) | Oral capsule (N/A) |
Reconstitution Steps
- 1
Verify the intact packaging and documented milligram strength of each Testoluten capsule.
- 2
Do not attempt reconstitution, dissolution, or aqueous extraction with bacteriostatic water, as the product is pre-measured for oral study.
- 3
Prepare the required oral dose with a measured volume of purified water.
- 4
Administer the capsule whole, typically documented approximately 15 to 20 minutes prior to a meal.
- 5
Reseal the original capsule container immediately to prevent humidity exposure.
Supplies Needed
Peptide Vial
Testoluten capsule bottle (20 mg per unit) containing dry oral biological extract.
Insulin Syringes (U-100)
Not required for oral capsule administration.
Bacteriostatic Water
Not required; encapsulated solid formulation needs no reconstitution.
Alcohol Swabs
Not required for non-injectable, oral bioregulator protocols.
Why researchers study it
Investigation of testes-derived signalling peptides on spermatogenic activity
Analysis of peptide bioregulator effects on Leydig cell androgen production
Evaluation of oral peptide bioavailability and tissue-specific trophic responses
Comparative screening against defined synthetic analogues such as Testagen
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Testoluten (Cytomax A-13) represents an orally administered peptide bioregulator derived from animal testicular tissues. Formulated within the framework of Khavinsonian gerontological science, it is classified as a parapharmaceutical extract rather than an isolated, synthetic chemical entity. The preparation is conventionally provided as encapsulated material targeting biological pathways associated with testicular cell function. Preclinical literature concerning male gonadal bioregulation largely stems from legacy research on related fractions like testilin or synthesized analogues like Testagen. These investigations suggest potential tissue-specific cellular interactions affecting spermatogenesis and local hormone dynamics, though Testoluten itself consists of a proprietary natural complex without Western regulatory approval. In contemporary laboratory protocols, Testoluten serves as a model for studying cellular signalling and tissue-derived trophic mechanisms in gonadal biology. Because it is administered exclusively in oral capsule form, standard peptide reconstitution and subcutaneous injection frameworks do not apply to this compound.
References
- 1.Khavinson, Neuroendocrinology Letters, 2002 — Peptides and Ageing
- 2.Boiko, Likars'ka Sprava, 1995 — Validation of prostatilen and testilin for treating male infertility
- 3.Khavinson et al., Advances in Gerontology, 2013 — Peptide bioregulators: a new class of geroprotectors
- 4.Khavinson et al., Molecules, 2020 — Peptides: prospects for use in the treatment of COVID-19
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allGlutathione 1500mg
Endogenous tripeptide antioxidant researched for cellular redox defense, hepatic conjugation pathways, and pigment regulation.
View ProtocolLL-37 5mg
LL-37 is an antimicrobial cathelicidin peptide investigated in laboratory research for immune modulation, tissue repair, and pathogen defense.
View ProtocolBronchogen 20mg
Synthetic short bioregulator tetrapeptide Ala-Glu-Asp-Leu investigated in preclinical airway models and epigenetic regulation.
View Protocol